RxDoctor Payments Data
★ My doctorsLook up a doctor →

Taiwen Chen, MD

Critical Care Medicine · Ocala, FLNPI 1629062385

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,038 of the $20,655 with a category attached, or 72.8%. Grifols USA, LLC accounts for 69.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $5,729 and has fallen 57.6% since, to $2,428 in 2023. Among critical care medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,655in general payments, 2019–2025

Across 109 payments — averaging $189.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols USA, LLC$14K
  • Mallinckrodt Hospital Products Inc.$2K
  • GSK$1K
  • AstraZeneca$837
  • Grifols Shared Services North America, Inc.$660
  • Daiichi Sankyo Inc.$213
  • plus $1K from 17 others
$19,500in research payments, 2019–2025

Across 1 payment — averaging $19,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$20K

What the payments were for

  • Consulting fees$3372%
  • Speaking & faculty fees$15,03873%
  • Travel & lodging$8634%
  • Food & beverage$4,41821%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Grifols USA, LLC23$14,297
Mallinckrodt Hospital Products Inc.1$2,150
GSK44$1,175
AstraZeneca8$837
Grifols Shared Services North America, Inc.1$660
Daiichi Sankyo Inc.2$213
Boehringer Ingelheim7$174
Insmed, Inc.2$145
Pacira Pharmaceuticals Incorporated1$125
Novo Nordisk1$125
Vapotherm Inc1$123
Sanofi1$121
Avanir Pharmaceuticals, Inc.1$121
Acelrx Pharmaceuticals, Inc.1$109
Genentech USA, Inc.4$66
Novartis2$48
Regeneron Healthcare Solutions, Inc.2$41
Mylan Specialty L.p.2$39
CSL Behring1$24
Sunovion Pharmaceuticals Inc.1$20
Gilead1$16
Philips North America LLC1$14
AbbVie1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,655 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida →

Medicare billing

Part B allowed, 2024
$39,852
Medicare patients
115
Services billed
255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other critical care medicine in Ocala

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →